![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » AM-Pharma B.V. Gains Fast Track Status for AKI Drug
AM-Pharma B.V. Gains Fast Track Status for AKI Drug
The FDA has awarded fast track status to AM-Pharma’s intravenous recombinant human alkaline phosphatase to treat acute kidney injury.
The candidate is being investigated in a Phase 2 trial in the U.S. and Europe to evaluate its effect on sepsis-associated AKI.
Upcoming Events
-
21Oct